Mazdutide vs Tirzepatide vs Retatrutide

Mazdutide vs Tirzepatide vs Retatrutide. Compare Mazdutide's dual GLP-1/glucagon mechanism to Tirzepatide and Retatrutide receptor profiles. Key Takeaways Mazdutide is a dual GLP-1/glucagon agonist: Developed by Innovent Biologics, it activates GLP-1 and glucagon receptors but NOT GIP Tirzepatide is a dual GLP-1/GIP agonist: FDA-approved compound activating different second receptor than Mazdutide Retatrutide is a triple agonist: Activates all three receptors (GLP-1, GIP, and glucagon) for most comprehensive coverage Glucagon receptor activation distinguishes Mazdutide: Different metabolic pathway from Tirzepatide despite both being "dual agonists" Regulatory status differs: Tirzepatide is FDA-approved; Mazdutide and Retatrutide are research compounds Understanding "Dual Agonist" Terminology Both Mazdutide and Tirzepatide are classified as "dual agonists"—but this terminology obscures a critical difference. They activate different second receptors. Tirzepatide combines GLP-1 with GIP (glucose-dependent insulinotropic polypeptide). Mazdutide combines GLP-1 with glucagon. These are fundamentally different metabolic pathways with distinct research implications. This distinction matters for researchers designing protocols around specific receptor systems. Understanding which pathways each compound engages is essential for proper study design. Receptor Profile Comparison The following table clarifies which receptors each compound activates: Receptor Mazdutide Tirzepatide Retatrutide GLP-1 ✓ ✓ ✓ GIP ✗ ✓ ✓ Glucagon ✓ ✗ ✓ Key observation: Mazdutide and Retatrutide share glucagon receptor activation—a pathway Tirzepatide does not engage. Retatrutide covers all three receptors, making it the most comprehensive option for multi-pathway research. Mazdutide: GLP-1 + Glucagon Mazdutide (IBI362) is developed by Innovent Biologics in partnership with Eli Lilly. It represents a distinct approach within the incretin peptide class. Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature. Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs. one Published Research The SURMOUNT and SURPASS trial programs provide extensive published documentation: SURMOUNT-1 through SURMOUNT-4: Obesity indication trials SURPASS-1 through SURPASS-5: Diabetes indication trials Extensive real-world evidence from post-marketing surveillance Published literature across multiple populations and demographics Retatrutide: GLP-1 + GIP + Glucagon Retatrutide represents the most comprehensive receptor coverage, activating all three pathways that Mazdutide and Tirzepatide divide between them. Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage. The TRIUMPH trial program documented observations across multiple dose cohorts. Comparative Analysis Mechanism Comparison Factor Mazdutide Tirzepatide Retatrutide Agonist Type Dual Dual Triple Second Receptor Glucagon GIP Both Developer Innovent/Lilly Eli Lilly Eli Lilly FDA Approved No Yes No (under review) Primary Trial Region China Global Global Research Application Selection When to consider Mazdutide: Research specifically examining glucagon pathway contributions without GIP confounding Studies comparing GLP-1/glucagon vs. GLP-1/GIP mechanisms Investigations into hepatic metabolism and energy expenditure Research protocols designed around Chinese clinical trial data When to consider Tirzepatide: Studies requiring FDA-approved compound status Research replicating established SURMOUNT/SURPASS protocols Investigations into dual incretin (GLP-1 + GIP) signaling Protocols requiring extensive published reference literature When to consider Retatrutide: Studies examining comprehensive multi-receptor activation Research comparing triple vs. dual agonist mechanisms Investigations requiring both glucagon AND GIP pathway activation Frontier research in incretin biology Key Distinctions: Glucagon vs. GIP Understanding why Mazdutide chose glucagon over GIP illuminates its distinct research applications. Glucagon Receptor Effects (Mazdutide, Retatrutide) Activates hepatic energy expenditure pathways Engages liver-based lipid metabolism Documented thermogenic effects in preclinical models Different mechanism from incretin-based satiety signaling GIP Receptor Effects (Tirzepatide, Retatrutide) Enhances GLP-1's incretin signaling Adipose tissue receptor expression documented Potential tolerability benefits in some published comparisons Synergistic effect with GLP-1 on insulin-related pathways Researchers selecting between these compounds should consider which pathway contributions are most relevant to their study objectives. Research-Grade Compound Availability For laboratory investigations into these GLP-1-class peptides, research-grade compounds are available from our peptide catalog . All three compounds are available in research quantities: Compound Available Sizes Starting Price (10 vials) Mazdutide 10mg × 10 $575 Tirzepatide 5mg–50mg × 10 $200 Retatrutide 5mg–30mg × 10 $238 Quality verification: We recommend sending samples to independent testing labs like Janoshik or Finnrick before use. Our guarantee: if independent testing shows anything below specifications, we'll reship or refund. Reconstitution math: Use our free Peptide Calculator to determine concentration, syringe units, and doses per vial for your research protocols. Frequently Asked Questions Is Mazdutide FDA approved? No. Mazdutide is developed by Innovent Biologics with trials primarily conducted in China. It has not received FDA approval and remains a research compound in the United States and most Western markets. What's the difference between Mazdutide and Tirzepatide? Both are dual agonists, but they activate different second receptors. Tirzepatide activates GLP-1 + GIP; Mazdutide activates GLP-1 + glucagon. These engage fundamentally different metabolic pathways despite both being classified as "dual agonists." Which compound has the most published clinical data? Tirzepatide has the most extensive published literature, with FDA approval, multiple completed Phase 3 trial programs (SURMOUNT, SURPASS), and extensive real-world evidence. Retatrutide has completed Phase 3 trials with data published. Mazdutide data is primarily from Chinese trial populations. Why would researchers choose Mazdutide over Retatrutide? Researchers specifically interested in GLP-1/glucagon combination WITHOUT GIP confounding would choose Mazdutide. This allows isolation of glucagon pathway contributions without the additional GIP variable present in Retatrutide. Can these compounds be used in combination research? Study design should follow established research methodology with appropriate clearance periods between compounds. Combination protocols are not well-documented in published literature for these specific peptides. Summary For GLP-1-class research, compound selection depends on which receptor pathways are most relevant to study objectives: Mazdutide: Dual GLP-1/glucagon for glucagon-specific pathway research without GIP Tirzepatide: Dual GLP-1/GIP with FDA approval and extensive published literature Retatrutide: Triple agonist for comprehensive multi-pathway research All three compounds are available at research-grade quality from PeptideStack. For detailed receptor comparisons including Semaglutide, see our three-compound comparison article. For tirzepatide-specific dose math, our tirzepatide dosage calculator handles the units-to-mg conversion across reconstitution volumes. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.